Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more
Ginkgo Bioworks Holdings (DNA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.094x
Based on the latest financial reports, Ginkgo Bioworks Holdings (DNA) has a cash flow conversion efficiency ratio of -0.094x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-47.68 Million) by net assets ($508.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ginkgo Bioworks Holdings - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Ginkgo Bioworks Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ginkgo Bioworks Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ginkgo Bioworks Holdings ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huabao Flavours & Fragrances Co Ltd Class A
SHE:300741
|
0.014x |
|
Xinjiang Zhundong Petroleum
SHE:002207
|
-0.939x |
|
GoldMining Inc
NYSE MKT:GLDG
|
-0.091x |
|
Yinchuan Xinhua Commercial Group Co Ltd
SHG:600785
|
0.170x |
|
Allied Blenders & Distillers Ltd
NSE:ABDL
|
N/A |
|
NUEV.EXP.TEX.INH.EO-016
F:B02
|
N/A |
|
Lingsen Precision Industries Ltd
TW:2369
|
-0.006x |
|
M. Dias Branco S.A. Indústria e Comércio de Alimentos
SA:MDIA3
|
0.064x |
Annual Cash Flow Conversion Efficiency for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual cash flow conversion efficiency of Ginkgo Bioworks Holdings from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $508.59 Million | $-171.06 Million | -0.336x | +24.64% |
| 2024-12-31 | $716.06 Million | $-319.58 Million | -0.446x | -65.71% |
| 2023-12-31 | $1.10 Billion | $-295.50 Million | -0.269x | -85.42% |
| 2022-12-31 | $1.74 Billion | $-252.20 Million | -0.145x | +10.30% |
| 2021-12-31 | $1.57 Billion | $-253.82 Million | -0.162x | +43.96% |
| 2020-12-31 | $470.05 Million | $-135.83 Million | -0.289x | -224.70% |
| 2019-12-31 | $501.85 Million | $-44.66 Million | -0.089x | -- |